Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1. Wright MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al. Am J Hematol 2022 Sep 15. doi: 10.1002/ajh.26730.

Read + Share

Amedeo Smart

Independent Medical Education

Wright MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, et al. Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1. Am J Hematol 2022 Sep 15. doi: 10.1002/ajh.26730.
PMID: 36106410